Extrapolation of In Vitro Metabolic and P-Glycoprotein-Mediated Transport Data to In Vivo by Modeling and Simulations

被引：2

作者：

Kato, Motohiro ^{[2
]}

Shitara, Yoshihisa ^{[3
]}

Kitajima, Masato ^{[4
]}

Tachibana, Tatsuhiko ^{[2
]}

Ishigai, Masaki ^{[2
]}

Horie, Toshiharu ^{[3
]}

Sugiyama, Yuichi ^{[1
]}

机构：

[1] Univ Tokyo, Dept Mol Pharmacokinet, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo, Japan

[2] Chugai Pharmaceut Co Ltd, Gotemba, Shizuoka, Japan

[3] Chiba Univ, Grad Sch Pharmaceut Sci, Dept Biopharmaceut, Chiba, Japan

[4] Fujitsu Kyushu Syst Ltd, Sawara Ku, Fukuoka, Japan

来源：

ENZYME- AND TRANSPORTER-BASED DRUG-DRUG INTERACTIONS: PROGRESS AND FUTURE CHALLENGES | 2010年

关键词：

DRUG-DRUG INTERACTIONS; QUANTITATIVE PREDICTION; 1ST-PASS METABOLISM; INHIBITION; ITRACONAZOLE; MECHANISM;

D O I：

10.1007/978-1-4419-0840-7_12

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Recently, a prediction method using in vivo K-i values for inhibitors of cytochrome P450 with a physiologically based pharmacokinetic modeling was proposed to improve the accuracy of the prediction. Also, a method to predict the alterations caused by drug-drug interactions mediated by intestinal cytochrome P450 3A4 or P-glycoprotein was introduced. In this chapter, these methods and computerized simulation method are shown.

引用

页码：299 / 315

页数：17

共 23 条

[1] Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine [J].

Bertelsen, KM ;

Venkatakrishnan, K ;

Von Moltke, LL ;

Obach, RS ;

Greenblatt, DJ .

DRUG METABOLISM AND DISPOSITION, 2003, 31 (03) :289-293

[2]

Food and Drug Administration, 2006, GUID IND DR IN PRESS

[3] New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process [J].

Huang, Shiew-Mei ;

Strong, John M. ;

Zhang, Lei ;

Reynolds, Kellie S. ;

Nallani, Srikanth ;

Temple, Robert ;

Abraham, Sophia ;

Al Habet, Sayed ;

Baweja, Raman K. ;

Burckart, Gilbert J. ;

Chung, Sang ;

Colangelo, Philip ;

Frucht, David ;

Green, Martin D. ;

Hepp, Paul ;

Karnaukhova, Elena ;

Ko, Hon-Sum ;

Lee, Jang-Ik ;

Marroum, Patrick J. ;

Norden, Janet M. ;

Qiu, Wei ;

Rahman, Atiqur ;

Sobel, Solomon ;

Stifano, Toni ;

Thummel, Kenneth ;

Wei, Xiao-Xiong ;

Yasuda, Sally ;

Zheng, Jenny H. ;

Zhao, Hong ;

Lesko, Lawrence J. .

JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (06) :662-670

[4] Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions [J].

Ishigam, M ;

Uchiyama, M ;

Kondo, T ;

Iwabuchi, H ;

Inoue, S ;

Takasaki, W ;

Ikeda, T ;

Komai, T ;

Ito, K ;

Sugiyama, Y .

PHARMACEUTICAL RESEARCH, 2001, 18 (05) :622-631

[5] Role of itraconazole metabolites in CYP3A4 inhibition [J].

Isoherranen, N ;

Kunze, KL ;

Allen, KE ;

Nelson, WL ;

Thummel, KE .

DRUG METABOLISM AND DISPOSITION, 2004, 32 (10) :1121-1131

[6] Database analyses for the prediction of in vivo drug-drug interactions from in vitro data [J].

Ito, K ;

Brown, HS ;

Houston, JB .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (04) :473-486

[7] Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? [J].

Ito, K ;

Chiba, K ;

Horikawa, M ;

Ishigami, M ;

Mizuno, N ;

Aoki, J ;

Gotoh, Y ;

Iwatsubo, T ;

Kanamitsu, S ;

Kato, M ;

Kawahara, I ;

Niinuma, K ;

Nishino, A ;

Sato, N ;

Tsukamoto, Y ;

Ueda, K ;

Itoh, T ;

Sugiyama, Y .

AAPS PHARMSCI, 2002, 4 (04) :xxx

[8] The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling [J].

Kato, Motohiro ;

Shitara, Yoshihisa ;

Sato, Hitoshi ;

Yoshisue, Kunihiro ;

Hirano, Masaru ;

Ikeda, Toshihiko ;

Sugiyama, Yuichi .

PHARMACEUTICAL RESEARCH, 2008, 25 (08) :1891-1901

[9] Intestinal first-pass metabolism of CYP3A4 substrates [J].

Kato, Motohiro .

DRUG METABOLISM AND PHARMACOKINETICS, 2008, 23 (02) :87-94

[10]

Kato Motohiro, 2003, Drug Metab Pharmacokinet, V18, P121, DOI 10.2133/dmpk.18.121

← 1 2 3 →